Respiratory Medicine
Volume 104, Issue 7 , Pages 995-1004 , July 2010

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

  • J.A. van Noord

      Affiliations

    • Department of Respiratory Diseases, Atrium medisch centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    • Corresponding Author InformationCorresponding author.
    • ,
  • J.-L. Aumann

      Affiliations

    • Department of Respiratory Diseases, Virga Jesse Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium
    • ,
  • E. Janssens

      Affiliations

    • Department of Respiratory Diseases, Ziekenhuis Oost-Limburg, Bessemerstraat 478, 3620 Lanaken, Belgium
    • ,
  • J.J. Smeets

      Affiliations

    • Department of Respiratory Diseases, Atrium medisch centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    • ,
  • J. Zaagsma

      Affiliations

    • Department of Molecular Pharmacology, University Centre for Pharmacy, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
    • ,
  • A. Mueller

      Affiliations

    • Department of Clinical Research, Boehringer Ingelheim bv, Comeniusstraat 6, 1817 MS Alkmaar, The Netherlands
    • ,
  • P.J.G. Cornelissen

      Affiliations

    • Department of Clinical Research, Boehringer Ingelheim bv, Comeniusstraat 6, 1817 MS Alkmaar, The Netherlands

Received 29 December 2009 ,Accepted 21 February 2010.

References 

  1. From the Global Strategy for the Diagnosis, Management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) update 2008. Available from: www.goldcopd.org (accessed: November 28, 2008).
  2. ATS/ERS Task Force Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  3. Dransfield MT, Bailey WC. Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach. Expert Opin Pharmacother. 2005;6:13–25
  4. Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ. 2005;330:640–644
  5. Decramer M. Tiotropium as essential maintenance therapy in COPD. Eur Respir J. 2006;15:51–57
  6. Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2008;42:1832–1842
  7. Friedman M, Della Cioppa G, Kottakis J. Formoterol for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy. 2002;22:1129–1139
  8. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging. 2001;18:441–472
  9. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, Di Marco F, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004;98:1214–1221
  10. van Noord JA, Aumann J-L, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214–222
  11. van Noord JA, Aumann J-L, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129:509–517
  12. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med. 2007;146:545–555
  13. Eguchi Y, Tateishi Y, Umeda N, Yoshikawa T, Kamoi H, Kanazawa H, et al. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD. Osaka City Med J. 2007;53:25–34
  14. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102:479–487
  15. Singh D, Brooks J, Hagan G, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592–598
  16. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511–1520
  17. Terzano C, Petroiann A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med. 2008;102:1701–1707
  18. Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med. 2009;103:516–524
  19. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. J COPD. 2009;6:17–25
  20. American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77–S120
  21. Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flow. Eur Respir J. 1993;6(Suppl. 16):5–40
  22. American Thoracic Society . Standardization of spirometry – 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136
  23. Mahler DA, Weinber DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751–758
  24. Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta-2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;328:1198–1203
  25. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136–1142
  26. Mahler DA, Witek TJ. The MCID of the transition dyspnea index is a total score of one unit. J COPD. 2005;2:99–103
  27. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327:1420–1425
  28. Calverley PMA, Lee A, Towse L, van Noord JA, Witek TJ, Kesten S. Effect of tiotropium on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58:855–860
  29. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995;8:1506–1513
  30. van Noord JA, Otte A, Smeets JJ, Bindels H, Mueller A, Cornelissen PJG. The effect of tiotropium, salmeterol and its combination on dynamic hyperinflation in COPD. Proc Am Thorac Soc. 2005;2:A542
  31. Briggs DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397–404
  32. Budd DC, Challiss RAJ, Young KW, Tobin AB. Cross-talk between m3-Muscarinic and β2-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol Pharmacol. 1999;56:813–823
  33. Meurs H, Roffel AF, Elzinga CRS, Zaagsma J. Muscarinic receptor – β-adrenoceptor cross-talk in airways smooth muscle. In:  Zaagsma J,  Meurs H,  Roffel AF editor. Muscarinic Receptors in Airways Diseases. Basel, Boston, London: Birkhäuser Verlag; 2001;p. 121–157
  34. Boterman M, Smits SRJG, Meurs H, Zaagsma J. Protein kinase C potentiates homologous desensitization of the β2-adrenoceptor in bovine tracheal smooth muscle. Eur J Pharmacol. 2006;529:151–156

☆ Study not registered in the Clinical Trials Registry; all patients were entered before implementation of the registry.

PII: S0954-6111(10)00087-9

doi: 10.1016/j.rmed.2010.02.017

Respiratory Medicine
Volume 104, Issue 7 , Pages 995-1004 , July 2010

Article Tools

* Image Usage & Resolution